companies / azafaros-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-18 json
| total_raised | 142,560,000142.6M | ○ |
|---|---|---|
| founded | 2018 | |
| hq | Leiden, Netherlands | |
| industry | unknown | |
| stage | series-b+ |
Clinical-stage biotech advancing nizubaglustat, an oral azasugar for lysosomal storage disorders affecting the brain. Targets patients with GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. Brain-penetrant chemistry from Leiden and Amsterdam UMC research is heading into two Phase 3 trials with a 132 million euro Series B.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-05-01 | series-b | 142,560,000142.6M | null | ○ |
LiteSpeed, Afterpay, Google Tag Manager, PHP, jquery 1.9.1
| fact | status | src |
|---|---|---|
| Series B, $142.6M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |